Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 22, 2026, 5:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Gemcitabine Clear all
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Capecitabine, Gemcitabine, Docetaxel, Stereotactic body radiation therapy (SBRT), Restaging review after radiation, Surgery, 5-Fluorouracil
Drug · Radiation · Other + 1 more
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 12, 2015 · Synced May 22, 2026, 5:05 AM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
BTH1704, IMPRIME PGG, Gemcitabine
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 30, 2015 · Synced May 22, 2026, 5:05 AM EDT
Completed Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Advanced Cancers, Lymphoma
Interventions
Azacitidine, Vorinostat, Gemcitabine, Busulfan, Melphalan, Dexamethasone, Caphosol, Glutamine, Pyridoxine, Rituximab
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
15 Years to 65 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 26, 2020 · Synced May 22, 2026, 5:05 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma
Interventions
Polatuzumab Vedotin, Rituximab, Gemcitabine, Oxaliplatin
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
7
States / cities
Jacksonville, Florida • Pembroke Pines, Florida • Ann Arbor, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2025 · Synced May 22, 2026, 5:05 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
bevacizumab, erlotinib hydrochloride, laboratory biomarker analysis
Biological · Drug · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 120 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 18, 2018 · Synced May 22, 2026, 5:05 AM EDT
Withdrawn Phase 2 Interventional
View directory record Official record
Conditions
Pancreatic Neoplasms
Interventions
Gemcitabine/Gemzar, Laparoscopic Distal pancreatectomy
Drug · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 5, 2016 · Synced May 22, 2026, 5:05 AM EDT
Completed Phase 3 Interventional
View directory record Official record
Conditions
Urinary Bladder Neoplasms
Interventions
larotaxel (XRP9881), gemcitabine, cisplatin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
337 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
52
States / cities
Anchorage, Alaska • Berkeley, California • Burbank, California + 46 more
Source: ClinicalTrials.gov public record
Updated May 4, 2016 · Synced May 22, 2026, 5:05 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Testicular Cancer
Interventions
Gemcitabine, Docetaxel, Melphalan, Carboplatin, Mesna, Ifosfamide, Etoposide, Stem Cell Transplant
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
12 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2024
U.S. locations
2
States / cities
Houston, Texas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 25, 2024 · Synced May 22, 2026, 5:05 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Brain Tumor, Brain Tumor, Recurrent, Brain Tumor, Refractory, Brain Tumor, Pediatric, Medulloblastoma, Medulloblastoma Recurrent, Medulloblastoma, Non-WNT/Non-SHH, Medulloblastoma, Non-WNT/Non-SHH, Group 3, Medulloblastoma, Non-WNT/Non-SHH, Group 4, Brain Cancer, CNS Cancer, CNS Tumor, CNS Neoplasm
Interventions
Prexasertib, Cyclophosphamide, Gemcitabine, filgrastim, peg-filgrastim
Drug · Biological
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
1 Year to 24 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 6, 2025 · Synced May 22, 2026, 5:05 AM EDT
Terminated Not applicable Interventional
View directory record Official record
Conditions
Intrahepatic Cholangiocarcinoma
Interventions
SIR-Spheres microspheres (Yttrium-90 Microspheres), Gemcitabine, Cisplatin
Device · Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Nov 17, 2024 · Synced May 22, 2026, 5:05 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
Interventions
carboplatin, gemcitabine, paclitaxel, surgery
Drug · Procedure
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
128
States / cities
Anchorage, Alaska • Glendale, Arizona • Mesa, Arizona + 89 more
Source: ClinicalTrials.gov public record
Updated May 26, 2013 · Synced May 22, 2026, 5:05 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Lung Cancer
Interventions
Pemetrexed, Gemcitabine
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced May 22, 2026, 5:05 AM EDT
Withdrawn Phase 3 Interventional
View directory record Official record
Conditions
Intrahepatic Cholangiocarcinoma
Interventions
Carboplatin, Cisplatin, Gemcitabine
Drug
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 18, 2018 · Synced May 22, 2026, 5:05 AM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Breast Cancer
Interventions
gemcitabine hydrochloride, pemetrexed disodium
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2008
U.S. locations
23
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Peoria, Illinois + 19 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2016 · Synced May 22, 2026, 5:05 AM EDT
Terminated Phase 2 Interventional
View directory record Official record
Conditions
Lymphoma, B-Cell
Interventions
Rituximab, Gemcitabine
Drug
Lead sponsor
Hoosier Cancer Research Network
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
9
States / cities
Elkhart, Indiana • Evansville, Indiana • Fort Wayne, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated May 1, 2011 · Synced May 22, 2026, 5:05 AM EDT
Completed Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma, Classical Hodgkin Lymphoma, Hodgkin Lymphoma
Interventions
Bendamustine, Gemcitabine, Nivolumab
Drug · Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced May 22, 2026, 5:05 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Bladder Cancer
Interventions
Gemcitabine and Cisplatin (DD GC)
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
8
States / cities
Basking Ridge, New Jersey • Commack, New York • Harrison, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2019 · Synced May 22, 2026, 5:05 AM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Breast Cancer
Interventions
erlotinib hydrochloride, gemcitabine hydrochloride
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
25
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Peoria, Illinois + 22 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2016 · Synced May 22, 2026, 5:05 AM EDT
Completed Phase 3 Interventional
View directory record Official record
Conditions
Pancreatic Neoplasms, Metastases, Neoplasm
Interventions
GEMZAR, ALIMTA
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
40
States / cities
Huntsville, Alabama • Fountain Valley, California • Fullerton, California + 37 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2006 · Synced May 22, 2026, 5:05 AM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Infiltrating Bladder Urothelial Carcinoma, Stage II Bladder Urothelial Carcinoma, Stage III Bladder Urothelial Carcinoma
Interventions
Gemcitabine Hydrochloride, Cisplatin, Pegfilgrastim, Conventional Surgery, Radical Cystectomy, Chemoradiotherapy
Drug · Biological · Procedure + 1 more
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
424
States / cities
Fairbanks, Alaska • Goodyear, Arizona • Phoenix, Arizona + 293 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced May 22, 2026, 5:05 AM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Disease, Hodgkin, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Non-Hodgkin
Interventions
SGN-35, gemcitabine
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
12 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
5
States / cities
Birmingham, Alabama • Palo Alto, California • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2014 · Synced May 22, 2026, 5:05 AM EDT
Withdrawn Not applicable Interventional
View directory record Official record
Conditions
Infiltrating Bladder Urothelial Carcinoma, Stage II Bladder Urothelial Carcinoma, Stage III Bladder Urothelial Carcinoma, Stage IV Bladder Urothelial Carcinoma
Interventions
Cisplatin, Gemcitabine Hydrochloride, Radical Cystectomy, Tumor Cell-Derived Vaccine Therapy
Drug · Procedure · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 16, 2017 · Synced May 22, 2026, 5:05 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional
View directory record Official record
Conditions
Relapsed/Refractory Diffuse Large B-cell Lymphoma
Interventions
Selinexor (combination therapy), Placebo matching for Selinexor (combination therapy), Rituximab (combination therapy), Gemcitabine (combination therapy), Dexamethasone (combination therapy), Cisplatin (combination therapy), Selinexor (continuous therapy), Placebo matching for Selinexor (continuous therapy)
Drug
Lead sponsor
Karyopharm Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
8
States / cities
Chandler, Arizona • Tucson, Arizona • Cerritos, California + 4 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced May 22, 2026, 5:05 AM EDT
Not listed Phase 1 Interventional
View directory record Official record
Conditions
Metastatic Pancreatic Cancer
Interventions
LCL161, Gemcitabine, nab-Paclitaxel
Drug
Lead sponsor
US Oncology Research
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
Incl Tyler, TX and Dallas, TX, Texas
Source: ClinicalTrials.gov public record
Updated Nov 9, 2015 · Synced May 22, 2026, 5:05 AM EDT